Evidence map›Paper›PMID 41155967›Full record

ReviewPharmaceutics2025

Therapeutic and Formulation Innovations in the Management of Canine Otitis Externa.

Yunmei Song, Sangseo Kim, Songhita Mukhopadhyay, Souha H Youssef, Jin Quan Eugene Tan, Emily Josephine Weir, Stephen W Page, Sanjay Garg

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yunmei SongCentre for Pharmaceutical Innovation (CPI), College of Health Sciences, Adelaide University, Adelaide, SA 5000, Australia.ORCID 0000-0003-0008-5895
Sangseo KimCentre for Pharmaceutical Innovation (CPI), College of Health Sciences, Adelaide University, Adelaide, SA 5000, Australia.ORCID 0000-0002-4773-6627
Songhita MukhopadhyayCentre for Pharmaceutical Innovation (CPI), College of Health Sciences, Adelaide University, Adelaide, SA 5000, Australia.
Souha H YoussefCentre for Pharmaceutical Innovation (CPI), College of Health Sciences, Adelaide University, Adelaide, SA 5000, Australia.
Jin Quan Eugene TanCentre for Pharmaceutical Innovation (CPI), College of Health Sciences, Adelaide University, Adelaide, SA 5000, Australia.
Emily Josephine WeirCentre for Pharmaceutical Innovation (CPI), College of Health Sciences, Adelaide University, Adelaide, SA 5000, Australia.
Stephen W PageNeoculi Pty Ltd., Burwood, VIC 3125, Australia.ORCID 0000-0001-5312-2149
Sanjay GargCentre for Pharmaceutical Innovation (CPI), College of Health Sciences, Adelaide University, Adelaide, SA 5000, Australia.ORCID 0000-0001-7253-2629

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Canine Otitis Externa (COE) is a challenging otological disorder in dogs which causes significant irritation and discomfort. This comprehensive review provides an extensive analysis of COE with emphasis on the fundamentals of the condition, starting with the basic anatomy of the canine external ear canal, followed by pathophysiology and diagnosis of COE. Furthermore, novel therapeutic interventions, formulation considerations, and challenges, with the perspective of future directions in the field of COE management, are described. Diagnostic models, including clinical examination, cytology, and susceptibility tests, are presented to provide an overview of the processes involved in detecting and selecting appropriate therapies for the management of COE. Moreover, this paper describes the limitations of current therapies with considerations for the selection of alternative novel treatments such as aromatherapy, acupuncture, bacteriophages, nutraceuticals, and nanomedicines. This review places particular emphasis on the pharmaceutical formulation of topical products used for COE treatment. Various factors, including osmotic pressure, safety profile, viscosity, bioadhesion, and formulation pH, must be considered when developing topical preparations. These parameters are critical in formulation development to enhance therapeutic outcomes and minimise potential side effects. Finally, potential advancements in COE management are highlighted, including the integration of microbial genomics and the significance of managing the microbiota. Overall, this review serves as a valuable resource for those interested in the future of topical treatment of COE by providing a deep understanding of diagnostic, therapeutic, and medical interventions for effective management.

Indexed as

canine otitis externadiagnosisformulation development

Identifiers

PMID41155967
PMCPMC12567363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.